Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Operating Income (2016 - 2025)

Historic Operating Income for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $2.9 million.

  • Sanara MedTech's Operating Income rose 27779.07% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.9 million, marking a year-over-year decrease of 2639.77%. This contributed to the annual value of -$6.7 million for FY2024, which is 5931.74% down from last year.
  • Sanara MedTech's Operating Income amounted to $2.9 million in Q3 2025, which was up 27779.07% from -$31348.0 recorded in Q2 2025.
  • Sanara MedTech's 5-year Operating Income high stood at $2.9 million for Q3 2025, and its period low was -$5.7 million during Q4 2024.
  • Moreover, its 5-year median value for Operating Income was -$1.9 million (2021), whereas its average is -$1.7 million.
  • In the last 5 years, Sanara MedTech's Operating Income tumbled by 242832.81% in 2024 and then skyrocketed by 27779.07% in 2025.
  • Sanara MedTech's Operating Income (Quarter) stood at -$3.4 million in 2021, then rose by 8.48% to -$3.1 million in 2022, then soared by 92.76% to -$225995.0 in 2023, then plummeted by 2428.33% to -$5.7 million in 2024, then skyrocketed by 151.48% to $2.9 million in 2025.
  • Its Operating Income was $2.9 million in Q3 2025, compared to -$31348.0 in Q2 2025 and -$2.1 million in Q1 2025.